Close encounters of the Serd kind
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Roche has a rare breast cancer setback
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
No Ameera glory for Sanofi
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
SABCS 2021 – Mutant benefit makes Emerald sparkle
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.
Delays hit Sanofi
The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.
Degrader battle sees Sanofi edged out for now
The French group was to have been first to report key Serd data this year, but has suffered delays as Roche and now Radius beat it to the punch.
Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Trillium buyout keeps premiums keen
The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.
